Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicle for RNA therapeutics, partly because of established lipid structure-activity relationships focused on formulation potency. Yet such knowledge has not extended to LNP immunogenicity. Here we show that the innate and adaptive immune responses elicited by LNPs are linked to their ionizable lipid chemistry. Specifically, we show that the amine headgroups in ionizable lipids drive LNP immunogenicity by binding to Toll-like receptor 4 and CD1d and by promoting lipid-raft formation. Immunogenic LNPs favour a type-1 T-helper-cell-biased immune response marked by increases in the immunoglobulins IgG2c and IgG1 and in the pro-inflammatory cytokines tumour necrosis factor, interferon γ and the interleukins IL-6 and IL-2. Notably, the inflammatory signals originating from these receptors inhibit the production of anti-poly(ethylene glycol) IgM antibodies, preventing the often-observed loss of efficacy in the LNP-mediated delivery of siRNA and mRNA. Moreover, we identified computational methods for the prediction of the structure-dependent innate and adaptive responses of LNPs. Our findings may help accelerate the discovery of well-tolerated ionizable lipids suitable for repeated dosing.
Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d.
可电离脂质中的胺基头部基团通过与受体 TLR4 和 CD1d 结合,驱动对脂质纳米颗粒的免疫反应
阅读:5
作者:Chaudhary Namit, Kasiewicz Lisa N, Newby Alexandra N, Arral Mariah L, Yerneni Saigopalakrishna S, Melamed Jilian R, LoPresti Samuel T, Fein Katherine C, Strelkova Petersen Daria M, Kumar Sushant, Purwar Rahul, Whitehead Kathryn A
| 期刊: | Nature Biomedical Engineering | 影响因子: | 26.600 |
| 时间: | 2024 | 起止号: | 2024 Nov;8(11):1483-1498 |
| doi: | 10.1038/s41551-024-01256-w | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
